Comparative protein binding of Taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin, in human plasma in vitro
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, T. K. | - |
dc.contributor.author | Yoo, H. H. | - |
dc.contributor.author | Kim, E. J. | - |
dc.contributor.author | Sa, J. H. | - |
dc.contributor.author | Lee, B. -Y. | - |
dc.contributor.author | Park, Jeong Hill | - |
dc.date.accessioned | 2021-06-23T06:52:12Z | - |
dc.date.available | 2021-06-23T06:52:12Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 0031-7144 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/32160 | - |
dc.description.abstract | The purpose of this study was to evaluate the plasma-protein binding of docetaxel in two different formulations, Taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin (HP-beta-CD), in human plasma in vitro, using equilibrium dialysis. Unbound docetaxel concentration in the human plasma was determined by LC-MS/MS analysis. SID530 showed a plasma-protein binding profile comparable to that of Taxotere in the clinically relevant concentration range of docetaxel. In both formulations, the unbound fraction of docetaxel increased in a concentration-dependent biphasic manner. The resulting data indicate that the excipient used in SID530, HP-beta-CD, generates similar effects as polysorbate 80 of Taxotere in terms of plasma-protein binding of docetaxel. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Govi Verlag Pharmazeutischer Verlag GmbH | - |
dc.title | Comparative protein binding of Taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin, in human plasma in vitro | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, H. H. | - |
dc.identifier.doi | 10.1691/ph.2012.1149 | - |
dc.identifier.scopusid | 2-s2.0-84867218407 | - |
dc.identifier.wosid | 000308851000007 | - |
dc.identifier.bibliographicCitation | Die Pharmazie, v.67, no.9, pp.789 - 791 | - |
dc.relation.isPartOf | Die Pharmazie | - |
dc.citation.title | Die Pharmazie | - |
dc.citation.volume | 67 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 789 | - |
dc.citation.endPage | 791 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CLINICAL PHARMACOKINETICS | - |
dc.subject.keywordPlus | UNBOUND DOCETAXEL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | UNBOUND DOCETAXEL | - |
dc.subject.keywordAuthor | CLINICAL PHARMACOKINETICS | - |
dc.subject.keywordAuthor | CANCER | - |
dc.identifier.url | https://www.ingentaconnect.com/content/govi/pharmaz/2012/00000067/00000009/art00007 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.